INTRAVASCULAR STENT
An expandable stent for implantation in a body lumen, such as an artery, is disclosed. The stent consists of a plurality of radially expandable cylindrical rings generally aligned on a common longitudinal stent axis and interconnected by one or more interconnecting links placed so that the stent is flexible in the longitudinal direction. The link pattern is optimized to enhance longitudinal flexibility and high longitudinal strength compression of the stent.
Latest Abbott Cardiovascular Systems Inc. Patents:
The present invention relates to expandable endoprosthesis devices, generally known as stents, which are designed for implantation in a patient's body lumen, such as a blood vessel to maintain the patency thereof. These devices are particularly useful in the treatment and repair of blood vessels after a stenosis has been compressed by percutaneous transluminal coronary angioplasty (PTCA) or percutaneous transluminal angioplasty (PTA) or removed by atherectomy or other means.
Stents are generally cylindrically-shaped devices which function to hold open and sometimes expand a segment of a blood vessel or other lumen such as a coronary artery. They are particularly suitable for use to support the lumen or hold back a dissected arterial lining which can occlude the fluid passageway therethrough.
A variety of devices are known in the art for use as stents and has included a plastically deformable wire mesh in a variety of patterns that is expanded after being placed intraluminally on a balloon catheter; helically wound coiled springs manufactured from an expandable heat sensitive metal; and self-expanding stents inserted in a compressed state and shaped in a zigzag pattern. One of the difficulties encountered using prior art stents involved maintaining the radial rigidity needed to hold open a body lumen while at the same time maintaining the longitudinal flexibility of the stent to facilitate its delivery and accommodate the often tortuous path of the body lumen. Other problems encountered by using prior art stents involve maintaining stent longitudinal flexibility and longitudinal stent compression. Some prior art stents are highly longitudinally flexible, however, these stents tend to experience higher longitudinal stent compression when the stent is subject to an axial load.
Another problem area for prior art stents has been the flexibility in the stent distal end. Many prior art stents have uniform longitudinal flexibility along their lengths. It may be desirable to have a stent with a higher degree of flexibility in the distal end to better track through tortuous calcified anatomy.
Another problem with prior art stents occurs when a first stent is deployed in a blood vessel, and the deployed stent blocks access to a side branch vessel which can reduce blood flow to the side branch vessel and block access for deployment of a second stent in the side branch vessel.
The devices disclosed herein overcome the deficiencies of the prior art devices and provide stents having a high degree of longitudinal flexibility, increased radial strength, enhanced side branch access, and improved longitudinal strength compression.
SUMMARY OF THE INVENTIONThe present devices are directed to stents having enhanced longitudinal flexibility and high longitudinal strength compression. The stents have greater flexibility along their longitudinal axis to facilitate delivery through tortuous body lumens but remain highly stable and resistant to longitudinal compression incurred when another device tries to cross the deployed stent. The unique link patterns of the stents permit both greater longitudinal flexibility and higher longitudinal strength compression compared to prior art stents.
Each of the different embodiments of stents of the present invention includes a plurality of adjacent cylindrical rings which are generally expandable in the radial direction and arranged in alignment along a longitudinal stent axis. The cylindrical rings are formed in a serpentine wave pattern transverse to the longitudinal axis and contain a plurality of alternating peaks and valleys. At least one link extends between adjacent cylindrical rings and connects them to one another. These links insure minimal longitudinal contraction during radial expansion of the stent in the body vessel. The links can be positioned in differing configurations or patterns along the stent length to enhance stent retention on the delivery catheter, eliminate strut fractures, enhance longitudinal stent flexibility, and enhance longitudinal strength compression.
The resulting stent structures are a series of radially expandable cylindrical rings that are spaced longitudinally close enough so that small dissections in the wall of a body lumen may be pressed back into position against the lumenal wall, but not so close as to compromise the longitudinal flexibility of the stent both when being negotiated through the body lumens in their unexpanded state and when expanded into position. The serpentine patterns allow for an even expansion around the circumference by accounting for the relative differences in stress created by the radial expansion of the cylindrical rings.
Each of the stents of the present invention can be readily delivered to the desired lumenal location by mounting it on an inflatable member, such as a balloon of a delivery catheter, and passing the catheter-stent assembly through the body lumen to the implantation site. A variety of means for securing the stent to the inflatable member of the catheter for delivery to the desired location is available. It is presently preferred to compress or crimp the stent onto the uninflated balloon in a known manner.
Other features and advantages of the present invention will become more apparent from the following detailed description of the invention, when taken in conjunction with the accompanying exemplary drawings.
Prior art stent designs, such as the MULTILINK STENT® manufactured by Abbott Cardiovascular Systems, Inc., Santa Clara, Calif., include plurality of cylindrical rings that are connected by three connecting members between adjacent cylindrical rings. Each of the cylindrical rings is formed of a repeating pattern of U-, Y-, and W-shaped members, typically having three repeating patterns forming each cylindrical ring. A more detailed discussion of the configuration of the MULTILINK STENT® can be found in U.S. Pat. No. 5,569,295 (Lam) and U.S. Pat. No. 5,514,154 (Lau et al.), whose contents are hereby incorporated by reference.
One embodiment of the present stent is shown in
The delivery catheter 11 onto which stent 10 is mounted is similar to a conventional balloon dilatation catheter for angioplasty procedures. The balloon 14 may be formed of suitable materials such as polyethylene, polyethylene terephthalate, polyvinyl chloride, nylon, and ionomers such as SURLYN® manufactured by the Polymer Products Division of the DuPont Company. Other polymers also may be used.
In order for stent 10 to remain in place on balloon 14 during delivery to the artery 15, stent 10 is compressed or crimped onto balloon 14.
The delivery of stent 10 to a coronary artery, for example, is accomplished in the following manner. Stent 10 is first mounted onto inflatable balloon 14 on the distal extremity of delivery catheter 11. Stent 10 may be crimped down onto balloon 14 to obtain a low profile. The catheter-stent assembly can be introduced within the patient's vasculature in a conventional technique through a guiding catheter (not shown). Guidewire 18 is disposed through the arterial section. The catheter-stent assembly is then advanced over guidewire 18 within artery 15. Balloon 14 of catheter 11 is inflated to expand stent 10 against the inside of artery 15, which is illustrated in
In general, stent 10 serves to hold open artery 15 after catheter 11 is withdrawn, as illustrated in
In one embodiment, shown in
In the
In another embodiment, as shown in
In another embodiment, shown in
In the stent embodiments shown in
In another embodiment, shown in
In another embodiment, shown in
In the
In
In the
In
In the embodiments shown in
In the embodiment shown in
In the embodiment shown in
In the
In
One important feature of all of the embodiments of the present invention is the capability of the stents to expand from a low-profile diameter to a diameter much greater than heretofore was available, while still maintaining structural integrity in the expanded state and remaining highly flexible. Due to the novel structures, the stents of the present invention can have an overall expansion ratio of about 1.0 up to about 5.0 times the original diameter, or more, using certain compositions of stainless steel or cobalt chrome. For example, a 316L stainless steel stent or L605 cobalt chrome stent of the invention can be radially expanded from a diameter of 1.2 mm up to a diameter of about 5.75 mm, which deforms the structural members beyond the elastic limit. The stents still retain structural integrity in the expanded state and will serve to hold open the vessel in which they are implanted. Materials other than stainless steel (316L) may afford higher or lower expansion ratios without sacrificing structural integrity.
The stents of the present invention can be made in many ways. The preferred method of making the stent is to cut a thin-walled tubular member, such as a stainless steel or cobalt chrome tubing, to remove portions of the tubing in the desired pattern for the stent, leaving relatively untouched the portions of the metallic tubing which are to form the stent. It is preferred to cut the tubing in the desired pattern by means of a machine-controlled laser which is well known in the art. Electropolishing the stent is also well known in the art.
The stent tubing may be made of a suitable biocompatible material such as stainless steel, titanium, cobalt-chromium, tantalum, super-elastic (nickel-titanium) NiTi alloys and even high strength thermoplastic polymers. When stainless steel is utilized, the stainless steel can be one-eighth hardened due to a straightening process and then annealed to make the stent plastically deformable to thus remove intrinsic recoil post deployment. The stent diameters are very small, so the tubing from which it is made must necessarily also have a small diameter. For stents implanted in other body lumens, such as PTA applications in larger vessels like the renal artery, the dimensions of the tubing are correspondingly larger. The diameters and tubing wall thickness of the stents can vary according to a particular application and are known in the art. While it is preferred that the stents be made from laser cut tubing, those skilled in the art will realize that the stent can be laser cut from a flat sheet and then rolled up in a cylindrical configuration with the longitudinal edges welded or similarly joined to form a cylindrical shape.
It is preferred that the disclosed stent 10 have a constant strut thickness. In one embodiment, the radial thickness of all of the rings and links is approximately 68 micron. In another embodiment the thickness might be as large as 120 micron. While this dimension can vary depending upon the particular application, the 73 micron radial thickness provides optimum balance of flexibility to the stent, conformability to the vessel upon expansion, adequate radiopacity for viewing using fluoroscopy or other means of viewing, and adequate hoop strength in holding the artery open after the stent has been expanded and delivery balloon deflated. In some embodiments, there are six peaks 42 in each of the six rings and the overall stent length is between 8 and 48 mm.
The stents may also be made of materials such as superelastic (sometimes called pseudo-elastic) nickel-titanium (NiTi) alloys. In this case, the stent would be formed full size but deformed diametrically (e.g. compressed) to a smaller diameter onto the delivery catheter to facilitate intraluminal delivery to a desired intraluminal site. The stress induced by the deformation transforms the stent from an austenite phase to a martensite phase to enable the compression into a capture sheath of the delivery catheter, and upon release of the compressive pressure when the stent reaches the desired intraluminal location, allows the stent to fully expand into the vessel due to the transformation of the nitinol back to the more stable austenite phase.
The present invention stent is ideally suited for drug delivery (i.e., delivery of a therapeutic agent) since it has a relatively uniform ratio of stent versus open surface area which ensures uniform distribution of drugs delivered within the vessel. Typically, a polymer is coated onto the stent of the type disclosed in U.S. Pat. Nos. 6,824,559 and 6,783,793 which are incorporated herein by reference.
These bioactive agents can be any agent, which is a therapeutic, prophylactic, or diagnostic. These agents can have anti-proliferative or anti-inflammatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic, antioxidant as well as cystostatic agents. Examples of suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. Some other examples of other bioactive agents include antibodies, receptor ligands, enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. Examples of anti-proliferative agents include rapamycin and its functional or structural derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), and its functional or structural derivatives, paclitaxel and its functional and structural derivatives. Examples of rapamycin derivatives include methyl rapamycin, ABT-578 (Zotarolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin. Examples of paclitaxel derivatives include docetaxel. Examples of antineoplastics and/or antimitotics include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. ADRIAMYCIN® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. MUTAMYCIN® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax a (Biogen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name MEVACOR® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprus side, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), nitric oxide or nitric oxide donors, super oxide dismutases, super oxide dismutase mimetic, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), estradiol, anticancer agents, dietary supplements such as various vitamins, and a combination thereof. Examples of anti-inflammatory agents including steroidal and non-steroidal anti-inflammatory agents include tacrolimus, dexamethasone, clobetasol, combinations thereof. Examples of such cytostatic substance include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. CAPOTEN® and CAPOZIDE® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. PRINIVIL® and PRINZIDE® from Merck & Co., Inc., Whitehouse Station, N.J.). An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, bioactive RGD, and genetically engineered epithelial cells. The foregoing substances can also be used in the form of prodrugs or co-drugs thereof. The bioactive agents also include metabolites of the foregoing substances and prodrugs of these metabolites. The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents which are currently available or that may be developed in the future are equally applicable.
While the invention has been illustrated and described herein in terms of its use as intravascular stents, it will be apparent to those skilled in the art that the stents can be used in other instances in all vessels in the body. Since the stents of the present invention have the novel feature of expanding to very large diameters while retaining their structural integrity, they are particularly well suited for implantation in almost any vessel where such devices are or may be used. This feature, coupled with limited longitudinal contraction (i.e., stent length change or foreshortening) of the stent when it is radially expanded, provides a highly desirable support member for all vessels in the body. Other modifications and improvements may be made without departing from the scope of the invention.
Claims
1. A stent, comprising:
- a tubular body having a distal end ring and a proximal end ring and a plurality of body rings therebetween;
- the end rings and the body rings being positioned in an in-phase relationship;
- the end rings and the body rings being connected by links having a pattern of 3 links-2 links-3 links along the length of the stent; and
- the distal end ring being connected to a first body ring by three links, the first body ring being connected to a second body ring by two links, the second body ring being connected to a third body ring by three links, each of the remaining body rings being connected by the alternating pattern of 3-2-3-2-3 links, and the proximal end ring being connected to an adjacent body ring by three links.
2. The stent of claim 1, wherein the links are substantially linear or non-linear, more flexible.
3. The stent of claim 2, wherein the non-linear links have a both linear portion and a non-linear portion.
4. The stent of claim 3, wherein each of rings has a first crest and a second crest, the first crest being shorter than the second crest.
5. The stent of claim 4, wherein the stent has a compressed configuration and an expanded configuration, the non-linear portion of the link nests with the first crest when the stent is in the compressed configuration.
6. The stent of claim 1, wherein the 2-link configuration has linear links and the 3-link configuration has non-linear links.
7. The stent of claim 1, wherein the stent is formed from metal alloy taken from the group of metal alloys consisting of stainless steel, nickel-titanium, titanium, tantalum, and cobalt-chromium.
8. The stent of claim 1, wherein the stent is formed from a polymer.
9. A stent, comprising:
- a tubular body having a distal end ring and a proximal end ring and a plurality of body rings therebetween, the tubular body having a compressed diameter and an expanded implanted diameter;
- the end rings and the body rings being positioned in an in-phase relationship;
- the end rings and the body rings being connected by an alternating pattern of 2 links-2 links-3 links-2 links-2 links-3 links;
- the distal end ring being connected to a first body ring by two links, the first body ring being connected to a second body ring by two links, the second body ring being connected to a third body ring by three links, the third body ring being connected to a fourth body ring by two links, the fourth body ring being connected to a fifth body ring by two links, and the proximal end ring being attached to an adjacent body ring by three links.
10. The stent of claim 9, wherein the links are substantially linear or non-linear.
11. The stent of claim 10, wherein the non-linear links have a substantially linear portion and a non-linear portion.
12. The stent of claim 11, wherein each of rings has a first crest and a second crest, the first crest being shorter than the second crest.
13. The stent of claim 12, wherein the stent has a compressed configuration and an expanded configuration, the non-linear portion of the link nests with the first crest wherein the stent is in the compressed configuration.
14. The stent of claim 9, wherein the 2-link configuration has linear links and the 3-link configuration has non-linear links.
15. The stent of claim 9, wherein the stent is formed from metal alloy taken from the group of metal alloys consisting of stainless steel, nickel-titanium, titanium, tantalum, and cobalt-chromium.
16. The stent of claim 9, wherein the stent is formed from a polymer.
17. A stent, comprising:
- a tubular body having a plurality of cylindrical rings including a distal end ring and a proximal end ring and four body rings therebetween, the tubular body having a compressed diameter and an expanded implanted diameter;
- the distal end ring, a first body ring, and second body ring being positioned in an in-phase relationship;
- the proximal end ring, a third body ring, and a fourth body ring being positioned in an in-phase relationship;
- the second body ring and the third body ring being positioned in an out-of-phase relationship;
- two links connect the distal end ring to the first body ring and two links connect the first body ring to the second body ring; and
- three links connect the second body ring to the third body ring; three links connect the third body ring to the fourth body ring; and three links connect the fourth body ring to the proximal end ring.
18. The stent of claim 17, wherein the links are non-linear links.
19. The stent of claim 18, wherein the non-linear links have a linear portion and a non-linear portion.
20. The stent of claim 19, wherein each of rings has a first crest and a second crest, the first crest being shorter than the second crest.
21. The stent of claim 20, wherein the stent has a compressed configuration and an expanded configuration, the non-linear portion of the link nests with the first crest wherein the stent is in the compressed configuration.
22. A stent, comprising:
- a tubular body having a distal end ring, a proximal end ring, and a plurality of body rings therebetween;
- the end rings and the body rings being positioned in an in-phase relationship;
- the end rings and the body rings being connected by links having a pattern starting at the distal end ring of 3-2-3-2-3-3 links and ending at the proximal end ring; and
- the distal end ring being connected to a first body ring by three links, the first body ring being connected to a second body ring by two links, the second body ring being connected to a third body ring by three links, the third body ring being connected to a fourth body ring by two links, the fourth body ring being connected to a fifth body ring by three links, and the fifth body ring being connected to the proximal end ring by three links.
23. The stent of claim 22, wherein the links are substantially linear or non-linear more flexible.
24. The stent of claim 23, wherein the non-linear links have a substantially linear portion and a non-linear portion.
25. The stent of claim 24, wherein each of the rings has a first crest and a second crest, the first crest being shorter than the second crest.
26. The stent of claim 25, wherein the stent has a compressed configuration and an expanded configuration, the non-linear portion of the link nests with the first crest when the stent is in the compressed configuration.
27. The stent of claim 22, wherein the 2-link configuration has linear links and the 3-link configuration has non-linear links.
28. The stent of claim 22, wherein the stent is formed from metal alloy taken from the group of metal alloys consisting of stainless steel, nickel-titanium, titanium, tantalum, and cobalt-chromium.
29. The stent of claim 22, wherein the stent is formed from a polymer.
30. A stent, comprising:
- a tubular body having a distal end ring and a proximal end ring and a plurality of body rings therebetween, the tubular body having a compressed diameter and an expanded implanted diameter;
- the end rings and the body rings being positioned in an in-phase relationship;
- the end rings and the body rings being connected by a link pattern of 2 links-2 links-3 links-2 links-2 links-3 links-3 links;
- the distal end ring being connected to a first body ring by two links, the first body ring being connected to a second body ring by two links, the second body ring being connected to a third body ring by three links, the third body ring being connected to a fourth body ring by two links, the fourth body ring being connected to a fifth body ring by two links, the fifth body ring being connected to a sixth body ring by three links, and the proximal end ring being attached to the sixth body ring by three links.
31. The stent of claim 30, wherein the links are substantially linear or non-linear.
32. The stent of claim 31, wherein the non-linear links have a substantially linear portion and a non-linear portion.
33. The stent of claim 32, wherein each of the rings has a first crest and a second crest, the first crest being shorter than the second crest.
34. The stent of claim 33, wherein the stent has a compressed configuration and an expanded configuration, the non-linear portion of the link nests with the first crest when the stent is in the compressed configuration.
35. The stent of claim 30, wherein the 2-link configuration has linear links and the 3-link configuration has are non-linear links.
36. The stent of claim 30, wherein the stent is formed from metal alloy taken from the group of metal alloys consisting of stainless steel, nickel-titanium, titanium, tantalum, and cobalt-chromium.
37. The stent of claim 30, wherein the stent is formed from a polymer.
Type: Application
Filed: Oct 31, 2022
Publication Date: Feb 16, 2023
Applicant: Abbott Cardiovascular Systems Inc. (Santa Clara, CA)
Inventors: Diem Ta (San Jose, CA), Erik Eli (Redwood City, CA), Senthil Eswaran (Sunnyvale, CA)
Application Number: 17/977,251